Pub. Date : 2015 Jan 2
PMID : 25475722
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 2 | In this study, we first established imatinib-resistant K562 CML cells, and then evaluated the effect of Adiponectin in reversing imatinib resistance. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 3 | The data presented here demonstrated that Adiponectin was able to reverse K562 resistance to imatinib in vitro and in vivo. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 4 | Additional data with molecular approaches suggested that the reversion of Adiponectin in imatinib resistance signals through AdipoR1 but not AdipoR2 to downregulate Bcr-Abl expression and effect in imatinib-resistant K562 CML cells. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 5 | Additional data with molecular approaches suggested that the reversion of Adiponectin in imatinib resistance signals through AdipoR1 but not AdipoR2 to downregulate Bcr-Abl expression and effect in imatinib-resistant K562 CML cells. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 6 | Taken together, our data showed that Adiponectin can reverse imatinib resistance in CML, and to a certain extent elucidate the mechanism of Adiponectin reversing imatinib resistance that may provide a new and promising approach in imatinib resistance management in CML therapy. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 7 | Taken together, our data showed that Adiponectin can reverse imatinib resistance in CML, and to a certain extent elucidate the mechanism of Adiponectin reversing imatinib resistance that may provide a new and promising approach in imatinib resistance management in CML therapy. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |
| 8 | Taken together, our data showed that Adiponectin can reverse imatinib resistance in CML, and to a certain extent elucidate the mechanism of Adiponectin reversing imatinib resistance that may provide a new and promising approach in imatinib resistance management in CML therapy. | Imatinib Mesylate | adiponectin, C1Q and collagen domain containing | Homo sapiens |